Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus (Q41471229)

1 October 2017

1 reference

title

Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus (English)

1 reference

1 October 2017

Lewis JS 2nd

1

1 reference

1 October 2017

Terriff CM

series ordinal

2

1 reference

1 October 2017

Coulston DR

series ordinal

3

1 reference

1 October 2017

Garrison MW

series ordinal

4

1 reference

1 October 2017

publication date

1 March 1997

1 reference

1 October 2017

published in

Clinical Therapeutics

1 reference

1 October 2017

volume

19

1 reference

1 October 2017

issue

2

1 reference

1 October 2017

page(s)

187-214

1 reference

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Safety and activity of saquinavir in HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Protease inhibitors fly through FDA

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Renal failure after treatment with ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Ritonavir and renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Indinavir nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

1 reference

7 January 2021

Ordered accumulation of mutations in HIV protease confers resistance to ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

Resolution of refractory AIDS-related mucosal candidiasis after initiation of didanosine plus saquinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2897%2980110-5

7 January 2021

10.1016/S0149-2918(97)80110-5

Identifiers

DOI

1 reference

1 October 2017

1 reference